Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Chronic kidney disease
•
Nephrology
What is your approach to managing patients with suspected osmotic nephrosis from monthly IVIG infusions?
Related Questions
Would you consider restarting a SGLT2i at a reduced dose in a patient who you previously discontinued the medication because of an associated significant decline in eGFR?
Would you recommend AV fistula placement in a CKD Stage 5 patient who is over the age of 80?
Would you recommend oral or intravenous iron in a chronic kidney disease stage 4 patient who is not on an ESA and has a hemoglobin of 12.7 g/dl and an iron saturation of less than 20%?
Are recurrent UTIs a contraindication to SGLT2i use?
Below what eGFR would you consider discontinuing lithium in a bipolar disorder patient with chronic kidney disease?
Do you avoid ESA use in patients with anemia and chronic kidney disease who also have APLS and risk for thrombosis?
Would you consider using finerenone for proteinuric CKD associated with type 1 diabetes mellitus?
What are your management strategies for patients with chronic kidney disease attributed to deferasirox use who require frequent blood products for a hematologic disorder?
For patients with microscopic hematuria, do you prefer a lab submitted urinalysis sample undergoes automated urine analysis or microscopic analysis by laboratory staff for quantification of red blood cells?
What is the role for iothalamate clearance testing for glomerular filtration estimation in patients with chronic kidney disease?
